HDAC inhibitors affect cancer cells by cell-cycle arrest, by promoting differentiation or apoptosis, and by affecting angiogenesis and the immune system through upregulation of tumor antigens (6,12,23). This evidence concerns the gene HDAC9 and neoplasm.